Clinical Trials Directory

Trials / Unknown

UnknownNCT03364920

Serum Maresin-1 Predicts the Severity of Severe Acute Pancreatitis

Serum Maresin-1 Level Predicts the Disease Severity and Clinical Outcomes of Severe Acute Pancreatitis Patients

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Weiqin Li · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

This is a retrospective study about serum Maresin-1 level in different severe acute pancreatitis patients. The investigators want to study the correlation between the level of serum Maresin-1 and the severity of SAP, of course the clinical outcomes. The investigators want to find some biomarkers and strategy target drugs of severe acute pancreatitis.

Conditions

Timeline

Start date
2018-01-01
Primary completion
2019-01-01
Completion
2020-01-01
First posted
2017-12-07
Last updated
2017-12-07

Source: ClinicalTrials.gov record NCT03364920. Inclusion in this directory is not an endorsement.

Serum Maresin-1 Predicts the Severity of Severe Acute Pancreatitis (NCT03364920) · Clinical Trials Directory